AIkido Pharma Inc. (AIKI)
AIKIPrice: $3.56
Fair Value: 🔒
🔒score
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC... more
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therap... more
Description
Shares
| Market Cap | $19.53M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Anthony C. Hayes |
| IPO Date | 1980-03-18 | CAGR | 0.03% |
| Employees | 4 | Website | www.aikidopharma.com |
| Div. Yield | 11.34% | Payout Ratio | -0.37% |
| Buy Back Yield | — | Total Yield | 11.34% |
AIKI chart loading...
Fundamentals
Technicals
| Enterprise Value | $-6.56M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 1.38 | P/B Ratio | 0.81 |
| P/CF Ratio | -10.01 | P/FCF Ratio | -10.34 |
| EPS | — | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 779.05% | Gross Margin | 1% |
| Operating Margin | -1.09% | Profit Margin | -0.36% |
| ROE | -0.37% | ROA | -0.17% |
| ROCE | -0.62% | Current Ratio | 3.65 |
| Quick Ratio | 3.65 | Cash Ratio | 0.57 |
| Debt/Equity | 0.03 | Interest Coverage | — |
| Altman Z Score | -3.14 | Piotroski Score | 4 |